Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma

References

• World Health Organization. Diffuse large B-cell lymphoma (Union for International Cancer Control 2014 review of cancer medicines on the WHO list of essential medicines). 2014. [cited 2019 Aug 8]. Available from: http://www.who.int/selection_medicines/committees/expert/20/applications/DiffuseLargeBCellLymphoma.pdf.
   Google Scholar
• Vitolo U, Trněný M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large b-cell lymphoma. J Clin Oncol. 2017;35(31):3529–3537.
   PubMed Web of Science ®Google Scholar
• Dornan D, Bennett F, Chen Y, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114(13):2721–2729.
   PubMed Web of Science ®Google Scholar
• Pfeifer M, Zheng B, Erdmann T, et al. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia. 2015;29(7):1578–1586.
   PubMed Web of Science ®Google Scholar
• Genentech, Inc. Highlights of prescribing information: POLIVY™ (polatuzumab vedotin-piiq) for injection, for intravenous use. 2019. [cited 2019 Aug 8]. Available from: https://www.gene.com/download/pdf/polivy_prescribing.pdf
   Google Scholar
• Phillips T, Brunvand M, Chen A, et al. Polatuzumab vedotin combined with obinutuzumab for patients with relapsed or refractory non-Hodgkin lymphoma: preliminary safety and clinical activity of a phase Ib/II study. Blood. 2016;128(22):622–622.
   Web of Science ®Google Scholar
• Palanca-Wessels MC, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16(6):704–715.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6(5):e254–e265.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Herrera AF, Matasar MJ, et al. Polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): updated results of a phase (Ph) Ib/II study. Abstract presented at 60th ASH Annual Meeting and Exposition. Annual Meeting of the American Society of Haematology. 2018 Dec 1–4; San Diego, CA.
   Google Scholar
• Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155–165.
   PubMedGoogle Scholar
• Lu D, Lu T, Stroh M, et al. A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities. Cancer Chemother Pharmacol. 2016;77(3):459–476.
   PubMed Web of Science ®Google Scholar
• Minchella K, Xu H, Al-Huniti N. Exposure-response methods and dose approval of new oncology drugs by FDA from 2005 to 2015. J Clin Oncol. 2016;34(15_suppl):2530–2530.
   Web of Science ®Google Scholar
• Lu D, Gillespie WR, Girish S, et al. Time-to-event analysis of polatuzumab vedotin-induced peripheral neuropathy to assist in the comparison of clinical dosing regimens. CPT Pharmacometrics Syst Pharmacol. 2017;6(6):401–408.
   PubMedGoogle Scholar
• Lu D, Jin JY, Gibiansky L, et al. Exposure-response analysis to assist selection of dose and treatment duration for polatuzumab vedotin as a single agent or in combination with rituximab for the treatment of B-cell lymphoma. Blood. 2015;126(23):1525–1525.
   PubMed Web of Science ®Google Scholar
• Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778–784.
   PubMed Web of Science ®Google Scholar
• Lu D, Lu T, Gibiansky L, et al. Integrated population pharmacokinetic model of conjugated and unconjugated cytotoxic agent after polatuzumab vedotin dosing in non-Hodgkin lymphoma. CPT Pharmacometrics Syst Pharmacol. 2020;9(1):48–59.
   PubMedGoogle Scholar
• Freise KJ, Jones AK, Eckert D, et al. Impact of venetoclax exposure on clinical efficacy and safety in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Pharmacokinet. 2017;56(5):515–523.
   PubMed Web of Science ®Google Scholar
• Zhu R, Poland B, Wada R, et al. Exposure-response-based product profile-driven clinical utility index for ipatasertib dose selection in prostate cancer. CPT Pharmacometrics Syst Pharmacol. 2019;8(4):240–248.
   PubMedGoogle Scholar
• Tilly H, Morschhauser F, Bartlett NL, et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Lancet Oncol. 2019;20(7):998–1010.
   PubMed Web of Science ®Google Scholar
• Ohmachi K, Niitsu N, Uchida T, et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2013;31(17):2103–2109.
   PubMed Web of Science ®Google Scholar
• Merchionne F, Quintana G, Gaudio F, et al. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis. Leuk Res. 2014;38(12):1446–1450.
   PubMed Web of Science ®Google Scholar
• Fung M, Jacobsen E, Freedman A, et al. Increased risk of infectious complications in older patients with indolent non-Hodgkin lymphoma exposed to bendamustine. Clin Infect Dis. 2019;68(2):247–255.
   PubMed Web of Science ®Google Scholar